title: Proliferative vitreoretinopathy and antivascular endothelial growth factor treatment.
authors.affiliation: Eye Research Center, Rassoul Akram Hospital, Iran University of Medical Sciences, Tehran, Iran.
authors.forename: K
authors.initials: K
authors.lastname: Ghasemi Falavarjani
authors.affiliation: Eye Research Center, Rassoul Akram Hospital, Iran University of Medical Sciences, Tehran, Iran.
authors.forename: M
authors.initials: M
authors.lastname: Modarres
mesh_terms: D020533:Angiogenesis Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D000818:Animals; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects / Q000627:therapeutic use; D000068258:Bevacizumab; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D058449:Intravitreal Injections; D000069579:Ranibizumab; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*; D018630:Vitreoretinopathy, Proliferative / Q000188:drug therapy*
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D005938:Glucocorticoids; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D000069579:Ranibizumab
references.citation: Ophthalmic Res. 2000 Jan-Feb;32(1):25-9
references.pmid: 10657752
references.citation: Graefes Arch Clin Exp Ophthalmol. 1982;219(6):268-71
references.pmid: 6761238
references.citation: Retina. 1997;17(1):44-50
references.pmid: 9051842
references.citation: Eye (Lond). 2014 May;28(5):576-80
references.pmid: 24556886
references.citation: Eye (Lond). 2014 Dec;28(12):1525
references.pmid: 25104739
references.citation: Am J Pathol. 2013 May;182(5):1659-70
references.pmid: 23582767
references.citation: Prog Retin Eye Res. 2014 May;40:16-34
references.pmid: 24412519